Compare, Analyse Natco Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
NATCO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,080348-   
Low Rs671251-   
Sales per share (Unadj.) Rs592.1103.5-  
Earnings per share (Unadj.) Rs188.4-26.1-  
Cash flow per share (Unadj.) Rs206.3-21.6-  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.681.3-  
Shares outstanding (eoy) m36.90168.78-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.52.9 51.1%   
Avg P/E ratio x4.6-11.5 -40.5%  
P/CF ratio (eoy) x4.2-13.9 -30.6%  
Price / Book Value ratio x1.13.7 28.5%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,31150,553 63.9%   
No. of employees `0004.84.3 112.5%   
Total wages/salary Rs m3,2563,173 102.6%   
Avg. sales/employee Rs Th4,522.54,069.9 111.1%   
Avg. wages/employee Rs Th674.0739.1 91.2%   
Avg. net profit/employee Rs Th1,439.0-1,025.5 -140.3%   
INCOME DATA
Net Sales Rs m21,84817,472 125.0%  
Other income Rs m404122 330.2%   
Total revenues Rs m22,25217,594 126.5%   
Gross profit Rs m9,284-3,028 -306.6%  
Depreciation Rs m662754 87.8%   
Interest Rs m154473 32.5%   
Profit before tax Rs m8,872-4,133 -214.7%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920258 743.5%   
Profit after tax Rs m6,952-4,403 -157.9%  
Gross profit margin %42.5-17.3 -245.2%  
Effective tax rate %21.6-6.2 -346.3%   
Net profit margin %31.8-25.2 -126.3%  
BALANCE SHEET DATA
Current assets Rs m21,30712,797 166.5%   
Current liabilities Rs m5,9207,200 82.2%   
Net working cap to sales %70.432.0 219.9%  
Current ratio x3.61.8 202.5%  
Inventory Days Days73111 66.0%  
Debtors Days Days107124 85.9%  
Net fixed assets Rs m14,9867,459 200.9%   
Share capital Rs m36981 454.9%   
"Free" reserves Rs m30,3530-   
Net worth Rs m30,76013,714 224.3%   
Long term debt Rs m04,819 0.0%   
Total assets Rs m37,15125,906 143.4%  
Interest coverage x58.6-7.7 -758.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.7 87.2%   
Return on assets %19.1-15.2 -126.1%  
Return on equity %22.6-32.1 -70.4%  
Return on capital %29.3-19.8 -148.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m7,3430-   
CASH FLOW
From Operations Rs m4,6361,491 310.9%  
From Investments Rs m-11,155-458 2,436.0%  
From Financial Activity Rs m6,5094,374 148.8%  
Net Cashflow Rs m-185,407 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.8 Rs / ZAR

Compare NATCO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: TTK HEALTHCARE  STRIDES PHARMA SCIENCE  JUBILANT LIFE SCIENCES  STERLING BIOTECH  AJANTA PHARMA  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views On News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - UNICHEM LAB COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS